Neumora Therapeutics

NMRA

Market cap $391M

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 10:15 a.m.

LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”) (NASDAQ: NMRA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint. KOASTAL-2 and KOASTAL-3 studies for navacaprant in MDD have increased enrollment; topline data is expected in Q2 2026, but success remains uncertain. NMRA-511 showed a promising signal in phase 1b for Alzheimer's Disease agitation, with an enhanced effect in patients with elevated anxiety.

Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies

LOS ANGELES--(BUSINESS WIRE)---- $NMRA--NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.

WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update.

NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m.

Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript